Phase 1b/2 study of blinatumomab in Japanese adults with relapsed/refractory acute lymphoblastic leukemia-Reference-Cited by-同舟云学术

Phase 1b/2 study of blinatumomab in Japanese adults with relapsed/refractory acute lymphoblastic leukemia

Published:2020-02-11 Issue:4 Volume:111 Page:1314-1323
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Kiyoi Hitoshi¹^ORCID,Morris Joan D.²,Oh Iekuni³,Maeda Yoshinobu⁴,Minami Hironobu⁵^ORCID,Miyamoto Toshihiro⁶^ORCID,Sakura Toru⁷,Iida Hiroatsu⁸,Tuglus Catherine A.²,Chen Yuqi²,Dos Santos Cedric⁹,Kalabus James⁹,Anderson Abraham²,Hata Tomoko¹⁰,Nakashima Yasuhiro¹¹,Kobayashi Yukio¹²¹³^ORCID

Affiliation:

1. Department of Hematology and Oncology Nagoya University Graduate School of Medicine Nagoya Japan

2. Amgen Inc. Thousand Oaks California USA

3. Jichi Medical University Tochigi‐ken Japan

4. Okayama University Hospital Okayama Japan

5. Medical Oncology/Hematology Kobe University Graduate School of Medicine and Hospital Kobe Japan

6. Department of Medicine and Biosystemic Science Kyushu University Graduate School of Medical Science Fukuoka Japan

7. Leukemia Research Center Saiseikai Maebashi Hospital Maebashi Japan

8. National Hospital Organization Nagoya Medical Center Nagoya Japan

9. Amgen Inc. South San Francisco California USA

10. Department of Hematology Nagasaki University Hospital Nagasaki Japan

11. Department of Hematology Graduate School of Medicine Osaka City University Osaka Japan